Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. sophomore Good
|
|
New words:
accrual, Adriamycin, aliquoting, allergic, andNutropin, AQare, assumption, atDecember, BEXXAR, Chi, CHOP, clai, competitor, contrast, cyclophosphamide, Cytoxan, DI, doxorubicin, ee, ERP, expec, exported, facilitate, gastrointestinal, gestational, GI, GSK, hav, Humira, implied, imum, incl, ing, intermediate, intravitreal, mailing, makin, member, methodology, Millennium, Min, ne, notified, ovarian, Pharmacopeia, Prader, procedure, rejecting, Remicade, respond, retinal, Roc, ron, routine, SAP, SGA, Simultaneously, smaller, software, statute, step, sterility, submission, turn, uded, unresectable, USP, VELCADE, waiting, wil, Willi, ZEVALIN, Zyflo
Removed:
alleged, capitalize, CLL, closely, collected, compensated, demonstrated, Eastern, effort, endothelial, entry, fluctuate, front, inimum, joint, lie, measure, mentioned, monitoring, peak, present, pretax, proceeded, proposed, prudent, published, pursue, receipt, representative, resolved, Retavase, secondary, shape, situation, sooner, stay, staying, stipulation, strategic, strategy, suit, supplement, targeted, therapeutic, vascular, VEGF, whichever
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.30 Purchase Agreement, Dated As of July 13, 2005, Among Genentech, Inc. and Citigroup Global Markets, Inc. and Goldman, Sachs & Co. As Representatives of the Initial Purchasers
- 10.31 Manufacturing and Supply Agreement Between Genentech, Inc. and Lonza Biologics, Inc. Dated December 7, 2003
- 10.32 Toll Manufacturing Agreement by and Between Wyeth, Acting Through Its Wyeth Pharmaceuticals Division, and Genentech, Inc. Dated September 15, 2004
- 15.1 Letter Regarding Unaudited Interim Financial Information
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended.
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002.
- PDF PDF Copy of Q3 2005 Form 10-Q (September 30, 2005)
Related press release
Genentech similar filings
External links